Figure 3 — High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16/CA125 mutations

Research Paper|Volume 12, Issue 11|pp. 10827–10843

High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16/CA125 mutations

Back to articleFigure 3(3 of 5)

100%

Figure 3.Association of MUC16 mutations with tumor microenvironment. (A) Distinct immune cells infiltration in MUC16 mutated and wild-type subgroups. (B) Distribution of immune-related signatures of samples stratified by MUC16 mutational status. (C) Distinct expression of immune checkpoints in MUC16 mutated and wild-type samples. * P < 0.05; ** P < 0.01; *** P < 0.001.